These studies are ongoing, with the exception of the aforementioned KEYNOTE-177 study, which demonstrated the efficacy of anti-PD-1 inhibitor therapy in the MMR-deficient population of colorectal cancer patients and conflicting results in the JAVELIN study of anti-PD-L1 therapy in non-small lung cancer, as well as ovarian cancer with BRCA1/2 mutations [65,66,67,68]. The gene discussed is CD274; the disease is ovarian carcinoma.